MediciNova (NASDAQ:MNOV) Stock Rating Upgraded by Zacks Research

MediciNova (NASDAQ:MNOV) was upgraded by stock analysts at Zacks Research to a “hold” rating in a report released on Tuesday,Zacks.com reports.

Several other research analysts have also recently weighed in on the stock. D. Boral Capital reissued a “buy” rating and set a $9.00 price target on shares of MediciNova in a research report on Friday, January 30th. Weiss Ratings restated a “sell (d-)” rating on shares of MediciNova in a research report on Monday, December 29th. HC Wainwright initiated coverage on shares of MediciNova in a research note on Monday. They set a “buy” rating and a $10.00 target price on the stock. Finally, Lucid Cap Mkts upgraded shares of MediciNova to a “strong-buy” rating in a report on Monday, January 5th. Two analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $8.00.

MediciNova Stock Performance

Shares of MediciNova stock opened at $1.41 on Tuesday. The business’s 50 day moving average price is $1.54 and its 200 day moving average price is $1.42. The company has a market cap of $69.40 million, a price-to-earnings ratio of -5.87 and a beta of 0.58. MediciNova has a one year low of $1.13 and a one year high of $1.96.

MediciNova (NASDAQ:MNOV) last issued its earnings results on Friday, February 20th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.05. The company had revenue of $0.15 million during the quarter. On average, analysts predict that MediciNova will post -0.24 EPS for the current fiscal year.

Hedge Funds Weigh In On MediciNova

Large investors have recently modified their holdings of the business. State Street Corp grew its holdings in shares of MediciNova by 10.9% during the 4th quarter. State Street Corp now owns 193,698 shares of the biopharmaceutical company’s stock worth $254,000 after purchasing an additional 19,100 shares during the period. Jane Street Group LLC purchased a new stake in MediciNova in the 4th quarter valued at about $214,000. StoneX Group Inc. acquired a new position in MediciNova in the fourth quarter valued at about $25,000. Goldman Sachs Group Inc. acquired a new position in MediciNova in the fourth quarter valued at about $35,000. Finally, Citadel Advisors LLC purchased a new position in MediciNova during the third quarter worth about $92,000. Institutional investors and hedge funds own 9.90% of the company’s stock.

MediciNova News Summary

Here are the key news stories impacting MediciNova this week:

• Positive Sentiment: HC Wainwright initiated coverage with a “Buy” rating and a $10 price target, a material bullish endorsement for a small-cap biotech that can attract new investor attention and trading interest. HC Wainwright Initiates Coverage on MediciNova (NASDAQ:MNOV)
• Positive Sentiment: The analyst model projects multi-year upside: HC Wainwright’s forecasts show MediciNova moving from near-term losses to profitability (projected EPS of $0.29 in FY2028, $1.90 in FY2029 and $3.02 in FY2030). That long-term earnings runway supports the high $10 target and could justify speculative buying by growth-oriented investors. HC Wainwright & Co. initiates coverage of MediciNova (MNOV) with buy recommendation
• Neutral Sentiment: HC Wainwright’s near-term quarterly estimates remain negative (Q1–Q3 2026: ~$0.06 loss per share; Q4 2026: ~$0.08 loss), and FY2026 is modeled at a loss — meaning any upside depends on successful execution and clinical/commercial progress rather than immediate earnings improvement.
• Negative Sentiment: Despite the bullish initiation, the stock is down today—likely reflecting that the market is weighing near-term negative EPS, small market cap/liquidity and skepticism over execution risk before the multi-year upside can be realized. Volume is modest and technicals (50/200-day moving averages near the current price) suggest limited conviction so far.

About MediciNova

MediciNova, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule therapeutics for neurodegenerative, inflammatory, fibrotic and oncological diseases. Founded in the late 1990s, the company advances its proprietary compounds through clinical trials and strategic partnerships, with a goal of addressing areas of high unmet medical need. MediciNova is headquartered in San Diego, California, and maintains a presence in Tokyo to support collaborations and regulatory interactions in Asian markets.

The company’s leading clinical asset, MN-166 (ibudilast), is an anti-inflammatory and neuroprotective agent originally approved in Japan for asthma and post-stroke dizziness.